FY2024 saw repeat raisers return in force - several companies that had raised before came back for more - alongside a strong showing from health, beverages and impact-focused ventures. These are the ten largest Birchal raises that closed in the 2024 financial year (1 July 2023 to 30 June 2024), by total raised.
1. Medigrowth — $3,226,050 from 2,013 investors. The medicinal-cannabis company led the year with a $3.2 million raise and more than 2,000 investors.
2. Naked Life — $2,949,549 from 996 investors. The non-alcoholic beverage group (and the No Nasties Project) rode the booming no- and low-alcohol trend to nearly $3 million.
3. Birchal — $2,317,186 from 1,110 investors. The platform returned to its own community for a $2.3 million round.
4. Philter Brewing — $2,151,460 from 1,287 investors. The Sydney independent brewery kept craft beer firmly on the leaderboard.
5. Cannaponics — $1,788,133 from 1,251 investors. Back for a second raise - the campaign behind the 'rallied the crowd twice' story - adding another $1.8 million.
6. X-Hemp — $1,500,433 from 927 investors. The Tasmanian industrial-hemp company brought a materials-and-sustainability angle to the field.
7. CrowdProperty — $1,405,573 from 254 investors. The property-development lending platform raised $1.4 million from a smaller, higher-conviction group of 254 investors.
8. Medicann Health — $1,405,310 from 1,096 investors. A second appearance for the medicinal-cannabis company in successive years.
9. Fremantle Seaweed — $1,214,405 from 959 investors. The blue-economy seaweed venture - later one of our featured success stories - raised over $1.2 million.
10. RecycleSmart — $1,106,562 from 991 investors. The on-demand recycling service made the list for what would become a multi-raise journey on the platform.
FY2024's signature was loyalty: repeat raisers like Cannaponics, Medicann and Birchal showed that a community, once built, can be returned to.
Explore current and past campaigns on Birchal.
This article is general information only and is not financial advice or an offer of securities. Past campaign performance is not indicative of future results. Investing in early-stage companies involves significant risk, including the loss of your investment. Always read the relevant CSF offer document and the general CSF risk warning before investing.
